iNtRON Biotechnology, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- -
- Established
- 1999-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
4
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)A Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011
Phase 1
Completed
- Conditions
- Acute Radiation Syndrome
- Interventions
- Drug: KMRC011 5μg or PlaceboDrug: KMRC011 10μg or PlaceboDrug: KMRC011 15μg or PlaceboDrug: KMRC011 25μg or PlaceboDrug: KMRC011 20μg or Placebo
- First Posted Date
- 2018-07-13
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Intron Biotechnology, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT03585803
- Locations
- 🇰🇷
Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of
A Study to Evaluate the Safety, PK, PD, Immunogenicity of N-Rephasin® SAL200 in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Methicillin-Resistant Staphylococcus AureusHealthy VolunteersAnti-Bacterial AgentsMethicillin-Sensitive Staphylococcus Aureus Infection
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Intron Biotechnology, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT03446053
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Phase IIa Clinical Study of N-Rephasin® SAL200
Phase 2
Terminated
- Conditions
- Staphylococcus Aureus BacteremiaAnti-Bacterial Agents
- First Posted Date
- 2017-03-24
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Intron Biotechnology, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT03089697
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Anti-Bacterial AgentsHealthy VolunteersMethicillin-Resistant Staphylococcus Aureus
- First Posted Date
- 2013-05-16
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Intron Biotechnology, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT01855048
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
News
No news found